Natco Pharma hits a 52-week high after firm reports Q4 results; know what Anil Singhvi suggests for mid-cap stock
Natco Pharma reported a 40 per cent rise in its profit after tax (PAT) to Rs 386 core in the fourth quarter from Rs 276 crore Year-on-Year (YoY). The pharma company's revenue from operations was up by 19 per cent to Rs 1,068 crore in the quarter under review from Rs 898 crore in the same quarter last fiscal.
![Natco Pharma hits a 52-week high after firm reports Q4 results; know what Anil Singhvi suggests for mid-cap stock](https://cdn.zeebiz.com/sites/default/files/2024/05/28/296050-natco-pharma-official-take.jpg?im=FitAndFill=(1200,900))
Natco Pharma shares started the trading session at Rs 1,108.95 each on Tuesday, which turned out to be its 52-week high. Photo: Natco Pharma official website